December saw shares of Rigel Pharmaceuticals (RIGL 3.84%) drop more than 20%. The tumble happened after Rigel's partner AstraZeneca (AZN -0.24%) released phase 2b data concerning their experimental rheumatoid arthritis drug fostamatinib. While the drug outperformed the placebo, it failed to beat AbbVie's (ABBV -2.40%) Humira. (AbbVie, formerly the branded pharmaceutical division of health care powerhouse Abbott Labs (ABT 0.55%), is now listed on the NYSE). In this video, Motley Fool health care analysts Max Macaluso and Brenton Flynn break down this story for investors.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Why Rigel Pharmaceuticals Lost Big in December
NASDAQ: RIGL
Rigel Pharmaceuticals

Rigel Pharmaceuticals took a big hit in December. Here's why.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned




*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.